Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.33 USD
Change Today -0.06 / -2.51%
Volume 61.3K
PSTI On Other Exchanges
Tel Aviv
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics Announces Publication of Scientific Study Regarding Placental eXpanded (PLX) Cells in Prominent Peer-Reviewed Journal Stem Cells

Pluristem Therapeutics Inc. announced the publication of a scientific study regarding PLacental eXpanded (PLX) cells in the prominent peer-reviewed journal Stem Cells. The paper, titled "Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation", describes the findings of a recent mechanism of action study conducted by independent scientists at the Berlin-Brandenburg Center for Regenerative Therapy at Charité - University Medicine Berlin. The paper was co-authored by scientists from the Charité and Pluristem. The study demonstrated mechanisms by which PLX cells and other mesenchymal stromal cells (MSC) influence the immune system in order to modulate immune reactions and to prevent immune reactions against the cells when they are administered as an off-the-shelf product (unmatched). It was demonstrated in vitro that MSC, and in particular PLX cells, control the induction of an immune response at several points. The main target for MSC and PLX cells in this process are dendritic cells, which are the key player in inducing a T-cell immune response. Moreover, in vivo data from patients suffering from critical limb ischemia who were treated with PLX cells in a phase I/II study confirmed that HLA-unmatched PLX cells did not provoke an immune response in immunocompetent patients. These findings confirm the feasibility of using PLX cells in an off-the-shelf manner, and explain the mechanisms that make this possible.

Pluristem Therapeutics, Inc.'s PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project

Pluristem Therapeutics, Inc. announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency'sAdaptive Pathways pilot project. The goal of the project is to improve timely access for patients to new medicines. It allows for early mar6Beting authorization of a therapy in a restricted patient population, followed by additional assessments and the possibility of later approval for use in broader patient populations. Critical limb ischemia (CLI), a severe blockage in the arteries of the legs which markedly reduces blood-flow, is associated with a significantly increased risk of leg amputation and death. It currently affects approximately one million people in the U.S., and the prevalence is expected to increase significantly in the coming decades. CLI therefore represents a major commercial opportunity. Acceptance of Pluristem's cells for the treatment of CLI into the Adaptive Pathways could significantly curtail the time and investment needed to bring this product to market.

Pluristem Therapeutics, Inc. Presents at Oppenheimer16th Annual Israeli Conference, May-10-2015

Pluristem Therapeutics, Inc. Presents at Oppenheimer16th Annual Israeli Conference, May-10-2015 . Venue: David Intercontinental Hotel, Tel-Aviv, Israel. Speakers: Zami Aberman, Executive Chairman and Chief Executive Officer.

Pluristem's Clinical Advisory Board Prepares Phase II Clinical Trials in Critical Limb Ischemia in Europe and Japan

Pluristem Therapeutics Inc. announced that its Clinical Advisory Board for Critical Limb Ischemia (CLI) concluded a key meeting in London, England. During the meeting, Clinical Advisory Board members, including Key Opinion Leaders in the treatment of CLI, outlined the Phase II study design and other critical components of advanced-stage trials for the Company's PLacental eXpanded (PLX) cells in the treatment of this peripheral artery disease. Pluristem has applied to conduct Phase II trials for CLI in regions with recently established rapid regulatory pathways, including the Accelerated Pathway for Regenerative Therapy in Japan and the Adaptive Pathway in the European Union. Two Phase I studies for CLI, previously completed in the U.S. and Germany, met all primary endpoints. Data from these trials suggested that the cells were safe and potentially efficacious at multiple dosage levels in this indication.

Pluristem Therapeutics, Inc., Annual General Meeting, May 26, 2015

Pluristem Therapeutics, Inc., Annual General Meeting, May 26, 2015., at 17:00 Israel Standard Time. Location: offices. Agenda: To elect nine directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified; to consider and approve by a nonbinding advisory vote, the compensation of its named executive officers; to ratify the selection of Kost Forer Gabbay & Kasierer, as independent registered public accounting firm of the company for the fiscal year ending June 30, 2015; and to consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $2.33 USD -0.06

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.07 USD +0.02
Caladrius Biosciences Inc $1.58 USD -0.07
Nuo Therapeutics Inc $0.20 USD +0.0004
StemCells Inc $0.43 USD +0.0193
Vericel Corp $3.50 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 445.6x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 386.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at